AP-3000 BLOOD GLUCOSE MONITORING SYSTEM, MAJOR GLUCOSE CONTROL SOLUTION

K103230 · Bestgen Biotech Corp. · CGA · Apr 24, 2012 · Clinical Chemistry

Device Facts

Record IDK103230
Device NameAP-3000 BLOOD GLUCOSE MONITORING SYSTEM, MAJOR GLUCOSE CONTROL SOLUTION
ApplicantBestgen Biotech Corp.
Product CodeCGA · Clinical Chemistry
Decision DateApr 24, 2012
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 862.1345
Device ClassClass 2
AttributesPediatric

Intended Use

The AP-3000 Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the alternative sites (palm, forearm, upper arm, calf, and thigh) for self testing by persons with diabetes at home. The AP-3000 Blood Glucose Monitoring Systems is intended for testing outside the body (in vitro diagnostic use). It is intended for use by lay users and should only be used by a single patient as an aid to monitor the effectiveness of diabetes control. It is intended to be used by a single person and should not be shared. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. The AP-3000multi Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the alternative sites (palm, forearm, upper arm, calf, and thigh) for self testing by persons with diabetes. The AP-3000multi Blood Glucose Monitoring Systems is intended for testing outside the body (in vitro diagnostic use). It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. This system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or diabetes mellitus, and is not intended for use on neonates.

Device Story

System comprises glucose meter, test strips, and control solutions; uses electrochemical biosensor technology with glucose oxidase enzyme. Input: capillary whole blood sample applied to test strip. Operation: amperometric measurement of glucose concentration. Output: quantitative blood glucose result displayed on LCD. AP-3000 intended for home self-testing by lay users; AP-3000multi intended for professional healthcare settings using single-use, auto-disabling lancing devices. Healthcare providers/patients use output to monitor diabetes control effectiveness. Benefits: provides rapid, quantitative glucose data to assist in diabetes management.

Clinical Evidence

Performance evaluated in laboratory and clinical settings by healthcare professionals and lay users. Studies confirmed system performance meets intended use requirements. No specific sensitivity/specificity metrics provided in summary.

Technological Characteristics

Amperometric electrochemical biosensor; Glucose Oxidase (Aspergillus niger) enzyme. Test range: 20-600 mg/dL. HCT range: 20-60%. Power: 2x AAA batteries (AP-3000/multi). Connectivity: Internal code selection. Features: LCD with backlight, strip ejection mechanism.

Indications for Use

Indicated for quantitative blood glucose measurement in patients with diabetes (excluding neonates) using fresh capillary whole blood from fingertip or alternative sites (palm, forearm, upper arm, calf, thigh). AP-3000 is for single-patient home use; AP-3000multi is for multi-patient professional healthcare use with auto-disabling lancing devices.

Regulatory Classification

Identification

A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

Special Controls

*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ # 510(k) Summary This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of 21 CFR 807.92. The Assigned 510(k) number is k103230 ### 1. Submitter's Identification Bestgen Biotech Corporation 7F., No.186, Jian-Yi Rd., 235, Jung-He City, Taipei, Taiwan Correspondence: Steven Shen Q.A./ Regulatory Manager Tel: +886-2-8227-2188 Ext 211 Fax: +886-2-8227-2178 E-mail: stevenshen@mail.bestgen.com.tw ### 2. Device Name Proprietary name: AP-3000 and AP-3000multi Blood Glucose Monitoring System Regulatory information: | A. Regulation section: | 21 CFR Section 862.1345 Glucose Test System<br>21 CFR Section 862.1660, Quality Control Material | |------------------------|----------------------------------------------------------------------------------------------------------------------------------------------| | B Classification: | Class II for 862.1345<br>Class I for 862.1660 | | C. Product Code: | CGA, Glucose Oxidase, Glucose<br>NBW, System, Test, Blood Glucose, Over The Counter<br>JJX, Quality Control Material (assayed and unassayed) | | D. Panel: | Chemistry (75) | ### 3. Intended Use ### 3.1 AP-3000 Blood Glucose Monitoring System The AP-3000 Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the alternative sites (palm, forearm, upper arm, calf, and 1 thigh) for self testing by persons with diabetes at home. The AP-3000 Blood Glucose Monitoring Systems is intended for testing outside the body (in vitro diagnostic use). It is intended for use by lay users and should only be used by a single patient as an aid to monitor the effectiveness of diabetes control. It is intended to be used by a single person and should not be shared. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. The AP-3000 Meter is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the alternative sites (palm, forearm, upper arm, calf, and thigh) for self testing by persons with diabetes at home. AP-3000 Blood Glucose Test Strips must be used with the AP-3000 Meter is intended for testing outside the body (in vitro diagnostic use). It is intended for use by lay users and should only be used by a single patient as an aid to monitor the effectiveness of diabetes control. It is intended to T . {1}------------------------------------------------ be used by a single person and should not be shared. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. The AP-3000 Blood Glucose Test Strips are in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the alternative sites (palm, forearm, calf, and thigh) for self testing by persons with diabetes at home. AP-3000 Blood Glucose Test Strips must be used the AP-3000 Blood Glucose Meter. The AP-3000 Blood Glucose Test Strips are intended for testing outside the body (in vitro diagnostic use). It is intended for use by lay users and should only be used by a single patient as an aid to monitor the effectiveness of diabetes control. It is intended to be used by a single person and should not be shared. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. MAJOR Level I/Level II Control Solution is for use with AP-3000 Blood Glucose Test Strips as a quality control check to verify the accuracy of blood glucose test results. # 3.2 AP-3000multi Blood Glucose Monitoring System The AP-3000multi Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the alternative sites (palm, forearm, calf, and thigh) for self testing by persons with diabetes. The AP-3000multi Blood Glucose Monitoring Systems is intended for testing outside the body (in vitro diagnostic use). It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. This system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or diabetes mellitus, and is not intended for use on neonates. The AP-3000multi Meter is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the alternative sites (palm, forearm, calf, and thigh) for self testing by persons with diabetes. AP-3000multi Blood Glucose Test Strips must be used with the AP-3000multi Meter. AP-3000multi Meter is intended for testing outside the body (in vitro diagnostic use). It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. This system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. The AP-3000multi Blood Glucose Test Strips are in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the alternative sites (palm, forearm, calf, and thigh) for self testing by persons with diabetes. AP-3000multi Blood Glucose Test Strips must be used with the AP-300multi Meter. AP-3000multi Blood Glucose Test Strips are intended for testing outside the body (in vitro diagnostic use). It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. This system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. MAIOR Level I/Level II Control Solution is for use with AP-3000multi meter and AP-3000multi Blood Glucose Test Strips as a quality control check to verify the accuracy of blood glucose test results. ### 4. Device Description The AP-3000 Blood Glucose Monitoring System consists of three main products: the meter, test strip, and control solutions. These products have been designed, tested, and proven to work together as a system accurate blood glucose test results. Use only AP-3000 test strips and MAJOR control solution with the AP-3000 Blood Glucose Monitoring System. The AP-3000multi Blood Glucose Monitoring System consists of three main products: the meter, test strip, and control solutions. These products have been designed, tested, and proven to work together as a system accurate blood glucose test results. Use only AP-3000multi test strips and MAJOR control solution with the AP-3000multi Blood Glucose Monitoring System. ### 5. Substantial Equivalence Information A. Predicate device name: AP-1000 Blood Glucose Monitoring System {2}------------------------------------------------ # B. Predicate K number: k090389 # C. Comparison with predicate: The new device of AP-3000/AP-3000multi Blood Glucose Monitoring System has the following similarities to the predicate device: | Similarities | | | |-----------------------|----------------------------------------|----------------------------------------| | Item | Device<br>(AP-3000/AP-3000multi BGMS) | Predicate<br>(AP-1000 BGMS, k090389) | | Detection Method | Amperometry | Amperometry | | Enzyme | Glucose Oxidase<br>(Aspergillus niger) | Glucose Oxidase<br>(Aspergillus niger) | | Test Range | 20-600 mg/dL | 20-600 mg/dL | | Temperature Range | 50 ~ 104°F (10 ~ 40°C) | 50 ~ 104°F (10 ~ 40°C) | | Open Use Time (Strip) | 90 days | 90 days | | Coding | Internal Code Selection | Internal Code Selection | | Differences | | | | | |--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|--|--| | | r Device<br>(AP-3000/AP-3000multi BGMS) | Predicate<br>(AP-1000 BGMS, k090389). | | | | Meter Size | 55mm x 88mm x26mm | 54mm x 93mm x 16 mm | | | | Meter Weight | 65 g (with battery) | 53 g (with battery) | | | | Strip Ejection | Yes | No | | | | LCD with Backlight | Yes | No | | | | Memory Capability | 488 measurements | 960 measurements | | | | Power | Two AAA batteries | One CR2032 3V lithium battery | | | | Humidity Range | < 85% | 20~80% | | | | Testing Time | 7 seconds | 6 seconds | | | | Sample Volume | 0.7 pl | 0.6 pl | | | | Sample Source | The glucose concentration is<br>measured with quantitative<br>capillary whole blood from the<br>fingertip, palm, forearm, upper<br>arm, calf, and thigh. | The glucose concentration is<br>measured with quantitative<br>capillary whole blood from the<br>fingertip. | | | | HCT Range | 20-60% | 30-55% | | | {3}------------------------------------------------ # 6. Test Principle The detection and measurement of glucose in blood is by an electrochemical biosensor technology using glucose oxidase. # 7. Performance Characteristics The performance of AP-3000/AP-3000multi Blood Glucose Monitoring System was studied in the laboratory and in clinical settings by healthcare professionals and lay users. The studies demonstrated that the performance of this system meets its intended use. # 8. Conclusion Based on the information provided in this submission, the AP-3000multi Glucose Monitoring System is substantially equivalent to the predicate AP-1000 Blood Glucose Monitoring System. {4}------------------------------------------------ # DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with its wings spread, along with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged in a circular pattern around the eagle. The text is in all caps and appears to be in a serif font. The logo is black and white. ### Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Bestgen Biotech Corporation c/o Mr. Steven Shen Ouality Assurance Manager 7F., No. 186, Jian-Yi Road, Jung-He City Taipei, Taiwan, 235, ROC k103230 Re: > Trade Name: AP-3000 Blood Glucose Monitoring System AP-3000multi Blood Glucose Monitoring System Regulation Number: 21 CFR §862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Code: CGA, NBW, JJX Dated: April 19, 2012 Received: April 23, 2012 # Dear Mr. Shen: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and minted to rollerice reporting (reporting of medical device-related adverse events) (21 007); medical Leoney reanufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). APR 2 4 2012 {5}------------------------------------------------ If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance ... You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm Sincerely yours, signature Countney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {6}------------------------------------------------ # Indications for Use # 510/k) Number: k103230 ### Device Name: AP-3000 Blood Glucose Monitoring System #### Indications for Use: The AP-3000 Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the alternative sites (palm, forearm, upper arm, calf, and thigh for self testing by persons with diabetes at home. The AP-3000 Blood Glucose Monitoring Systems is intended for testing outside the body (in vitro diagnostic use). It is intended for use by lay users and should only be used by a single patient as an aid to monitor the effectiveness of diabetes control. It is intended to be used by a single person and should not be shared. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. The AP-3000 Meter is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the alternative sites (palm, forearm, upper arm, calf, and thigh) for self testing by persons with diabetes at home. AP-3000 Blood Glucose Test Strips must be used with the AP-3000 Meter. The AP-3000 Meter is intended for testing outside the body (in vitro diagnostic use). It is intended for use by lay users and should only be used by a single patient as an aid to monitor the effectiveness of diabetes control. It is intended to be used by a single person and should not be shared. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. The AP-3000 Blood Glucose Test Strips are intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the alternative sites (palm, forearm, calf, and thigh) for self testing by persons with diabetes at home. AP-3000 Blood Glucose Test Strips must be used the AP-3000 Blood Glucose Meter. The AP-3000 Blood Glucose Test Strips are intended for testing outside the body (in vitro diagnostic use). It is intended for users and should only be used by a single patient as an aid to monitor the effectiveness of diabetes control. It is intended to be used by a single person and should not be shared. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. MAJOR Level I/Level II Control Solution is for use with AP-3000 Blood Glucose Test Strips as a quality control check to verify the accuracy of blood glucose test results. Prescription Use And/Or Over the Counter Use (21 CFR Part 801 Subpart C) (21 CFR Part 801 Subpart D) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) Q ch Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) k103230 Page 1 of 2 {7}------------------------------------------------ # Indications for Use # 510(k) Number: k103230 ### Device Name: AP-3000mutli Blood Glucose Monitoring System ### Indications for Use: The AP-3000multi Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the alternative sites (palm, forearm, upper arm, calf, and thigh) for self testing by persons with diabetes. The AP-3000multi Blood Glucose is intended for testing outside the body (in vitro diagnostic use). It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. This system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. The AP-300multi Meter is intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the alternative sites (palm, forearm, calf, and thigh) for self testing by persons with diabetes. AP-3000multi Blood Glucose Test Strips must be used with the AP-3000multi Meter. AP-3000multi Meter is intended for testing outside the body (in vitro diagnostic use). It is intended for multi-patient use in a professional healthcare setting; as an aid to monitor the effectiveness of diabetes control. This system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. The AP-3000multi Blood Glucose Test Strips are intended for use in the quantitative measurement of glucose in fresh capillary whole blood from the finger and from the alternative sites (palm, forearm, upper arm, calf, and thigh) for self testing by persons with diabetes. AP-3000multi Blood Glucose Test Strips must be used with the AP-3000multi Meter. AP-3000multi Blood Glucose Test Strips are intended for testing outside the body (in vitro diagnostic use). It is intended for multi-patient use in a professional healthcare setting, as an aid to monitor the effectiveness of diabetes control. This system is only used with single-use, auto-disabling lancing devices. It is not intended for the diagnosis of or screening for diabetes mellitus, and is not intended for use on neonates. MAJOR Level I/Level II Control Solution is for use with AP-3000multi meter and AP-3000multi Blood Glucose Test Strips as a quality control check to verify the accuracy of blood glucose test results. Prescription Use V (21 CFR Part 801 Subpart D) And/Or Over the Counter Use_ (21 CFR Part 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) B. Cline Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety k103230 510(k) Page 2 of 2
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%